Showing 3971-3980 of 9153 results for "".
- Alumis Closes $259 Million Financing to Help Launch Phase 3 Psoriasis Trial for Lead Asset ESK-001https://practicaldermatology.com/news/alumis-closes-259-million-financing-to-help-launch-phase-3-psoriasis-trial-for-lead-asset/2462267/In this year's largest privite biotech fundraise to date, Alumis announced $259 million Series C financing to initiate pivotal phase 3 clinical trials for its lead candidate ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe pl
- LEO Pharma Finalizes Acquisition of Spevigo® for Rare Dermatologic Diseaseshttps://practicaldermatology.com/news/leo-pharma-finalizes-acquisition-of-spevigo-for-rare-dermatologic-diseases/2483600/LEO Pharma has officially completed its acquisition of Spevigo® (spesolimab) from Boehringer Ingelheim, according to a press release from the manufacturer. The purchase represents the c
- Meta-Analysis IDs Promising Therapies for Hidradenitis Suppurativahttps://practicaldermatology.com/news/meta-analysis-ids-promising-therapies-for-hidradenitis-suppurativa/2475515/A new network meta-analysis comparing treatments for moderate to severe hidradenitis suppurativa (HS) shows several agents offering significantly improved efficacy over placebo. Researchers reviewed phase 2 and 3 randomized c
- Study: Lifileucel Shows Sustained Benefit in Advanced Melanoma Over 5 Yearshttps://practicaldermatology.com/news/lifileucel-shows-sustained-benefit-in-advanced-melanoma-over-5-years/2475031/Lifileucel showed sustained benefit and safety in a 5-year follow-up analysis of the phase II C-144-01 study in patients with advanced melanoma, according to a new study in the Journal of Clinical Oncology. Patien
- Survey Shows Variability in Hyaluronidase Use Among Practitionershttps://practicaldermatology.com/news/survey-shows-variability-hyaluronidase-use-among-practitioners/2463109/New research suggests there are inconsistencies in the use of hyaluronidase (HYAL) for the treatment of adverse events with hyaluronic acid (HA) fillers, suggesting a need for standardized guidelines. "With the growing popularity and administration of HA fillers, there is likely to be a c
- Novel Peptide T14 May Reflect Age and Photoaging in Human Skinhttps://practicaldermatology.com/news/novel-peptide-t14-may-reflect-age-and-photo-aging-in-human-skin/2461843/A novel peptide ‘T14’ may reflect age and photoaging in human skin, according to a study in Aging. T14 is a 14mer peptide derived from the C-terminus of acetylcholinesterase (AChE). Once cleav
- Midmark Gives Back: Trade-in Program Results in Nearly 1,000 Exam Tables Donated to World Visionhttps://practicaldermatology.com/news/midmark-gives-back-trade-in-program-results-in-nearly-1000-exam-tables-donated-to-world-vision/2461347/Midmark Corp.'s 2021 trade-in program collected 1,000 eligible exam tables. The tables were donated primarily to World Vision, where they are refurbished and delivered to clinics that provide health c
- ISDIN Launches Melatonik Nighttime Serumhttps://practicaldermatology.com/news/isdin-launches-melatonik-nighttime-serum/2457577/ISDIN's Melatonik nighttime serum formulated with melatonin, bakuchiol (a natural antioxidant with retinol-like properties) and Vitamin C, is now available. It was developed to help skin recover from the day and prepare it to fi
- Philips Rolls Out New Three-In-One Skincare Devicehttps://practicaldermatology.com/news/philips-rolls-out-new-three-in-one-skincare-device/2457997/Philips is introducing Philips VisaPure Advanced, a new three-in-one facial skincare tool. The new device works to remove impurities that have accumulated in pores resulting in lesser appearance of enlarged or clogged pores and blackheads, which c
- Valeant Announces Nominees For Election To Board Of Directorshttps://practicaldermatology.com/news/valeant-announces-nominees-for-election-to-board-of-directors/2458585/Valeant Pharmaceuticals International, Inc. announced the nominees for election to its Board of Directors at the 2016 Annual Meeting of Shareholders on June 14, 2016. As previoulsy announced, Joseph C. Papa has been named Valeant's